The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01586468
Recruitment Status : Completed
First Posted : April 26, 2012
Last Update Posted : April 26, 2012
Information provided by (Responsible Party):
Nuvo Research GmbH

Brief Summary:

Objectives To assess the efficacy and safety of WF10 infusions in the treatment of subjects with persistent allergic rhinitis.

Study Design Randomized, double-blind, placebo-controlled, parallel-group, single-centre trial.

Subjects 50 subjects (25 per treatment group) with history of persistent allergic rhinitis for at least 2 years prior to enrolment and a positive allergen skin test. Subjects will be required to have a minimum mean score ≥6 for the baseline Total Nasal Symptom Score (TNSS) (mean score of morning and evening reflective TNSS assessments for the 3 days prior to randomization and treatment.

Treatments At the first treatment visit (T1), subjects that comply with the inclusion and exclusion criteria will be randomized into one of two treatment groups: WF10, or placebo.

Each individual treatment dose of study drug solution is 0.5 mL/kg body weight, diluted into 500 mL saline solution. Treatment will be administered once daily for 5 consecutive days (Visits T1-T5) via intravenous infusion.

Condition or disease Intervention/treatment Phase
Allergic Rhinitis Drug: WF10 Drug: NaCl Solution Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Study Start Date : March 2010
Actual Primary Completion Date : September 2010
Actual Study Completion Date : November 2010

Arm Intervention/treatment
Placebo Comparator: NaCl Solution Drug: NaCl Solution
NaCl Solution

Experimental: WF10 0.5 ml/kg BW Drug: WF10
0.5 mg/kg B.W.

Primary Outcome Measures :
  1. TNSS [ Time Frame: 9 weeks ]

Secondary Outcome Measures :
  1. MiniRQLQ score, POHA score, and rhinometric and spirometric parameters [ Time Frame: 9 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. History of persistent allergic rhinitis for at least 2 years prior to enrolment. Concurrent history of asthma is permitted.
  2. Positive allergen skin test to the relevant allergen(s), performed within the previous 2 years prior to enrolment.
  3. Mean score ≥6 for the baseline Total Nasal Symptom Score (TNSS)
  4. Screening laboratory values within normal range, except those related to the primary disease, including eosinophil count, and elevated glucose is allowed.
  5. Age between 18 and 70 years, inclusive.
  6. The subject must be able to read and understand German well enough to answer the questions in the TNSS and Mini Rhinoconjunctivitis Quality of Life Questionnaire (MiniRQLQ), without any translation or explanation.
  7. If female, the subject:

    1. Cannot become pregnant because she is surgically sterile (hysterectomy or tubal ligation), or is postmenopausal for at least 6 months prior to the screening visit.


    2. Is not pregnant, with a negative pregnancy test at screening (confirmed at the baseline visit), and uses an acceptable method of contraception with a low failure rate (PEARL Index) (i.e. less than 1% per year) when used consistently and correct (including oral contraceptives, hormone implant, intrauterine device, , male sexual partner(s) surgically sterile, abstinence).
  8. Except for persistent allergic rhinitis, the subject is in reasonably good health, as determined by the discretion of the study investigator (based on the physical examination and electrocardiogram [ECG] results).
  9. The subject has signed an informed consent form.

Exclusion Criteria:

  1. Non-allergic rhinitis, rhinitis medicamentosa, idiopathic rhinitis or sinusitis.
  2. History of nasal surgery in the 6 months prior to enrolment.
  3. An upper respiratory or sinus infection within the 2 weeks prior to enrolment.
  4. Presence of a severely deviated septum, septal perforation, structural nasal defect or large nasal polyps causing obstruction.
  5. Use of intramuscular glucocorticosteroids in the 12 weeks prior to enrolment; use of oral, intravenous or medium or high daily dose inhaled glucocorticosteroids (as described in GINA guidelines - see App. III)) in the 4 weeks prior to enrolment; use of topical (nasal or ocular) glucocorticosteroids in the 2 weeks prior to enrolment. .
  6. Use of anti-IgE antibodies (e.g. omalizumab) in the 12 weeks prior to enrolment.
  7. Use of anti-leukotrienes (e.g. montelukast) in the 4 weeks prior to enrolment.
  8. Unwillingness to discontinue prohibited medications and avoid their use during the study (see section 10.1.5 for a complete list of prohibited medications).
  9. Severe haematopoetic, cardiovascular, hepatic, renal, neurological or psychiatric disease.
  10. Glucose-6-phosphate dehydrogenase deficiency (activity < 60% = < WHO class 4)
  11. A female subject who is lactating.
  12. Planned travel outside of the study area during the first 22 days of the study.
  13. Any infirmity, disability or geographical location that would limit compliance with the protocol.
  14. A subject who has previously been randomized into this study, received at least one dose of study treatment and been withdrawn from this trial will not be allowed to re-enter.
  15. Use of another investigational drug within the 30 days prior to screening.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01586468

Leipzig, Sachsen, Germany, 04109
Sponsors and Collaborators
Nuvo Research GmbH
Principal Investigator: Christian Gessner, M.D. POIS

Responsible Party: Nuvo Research GmbH Identifier: NCT01586468     History of Changes
Other Study ID Numbers: WF10-07-002
First Posted: April 26, 2012    Key Record Dates
Last Update Posted: April 26, 2012
Last Verified: February 2010

Additional relevant MeSH terms:
Rhinitis, Allergic
Nose Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Pharmaceutical Solutions